A groundbreaking study published in the November issue of Plastic and Reconstructive Surgery—the official medical journal of the American Society of Plastic Surgeons (ASPS)—has identified a potentially critical link between a patient’s history of COVID-19 and an increased risk of venous thromboembolism (VTE) following panniculectomy. As body contouring procedures continue to rise in popularity following the global surge in weight-loss interventions, this research offers a vital update to surgical risk assessment protocols.
Main Facts: The Intersection of Infection and Surgery
Panniculectomy, a surgical procedure designed to remove loose, hanging skin and fat from the lower abdomen, is often performed to resolve functional complications such as chronic rashes, infections, ulcers, and mobility restrictions following major weight loss. While these procedures are largely restorative, they carry inherent surgical risks, the most feared of which is VTE—a condition encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE).
The new research, led by Mary Newland, BS, a medical student at Penn State College of Medicine, posits that the physiological aftermath of a COVID-19 infection may linger in the vascular system, predisposing patients to blood clots long after their initial respiratory symptoms have resolved.
"Our findings suggest that past COVID may be an additional predisposing risk factor for VTE among patients undergoing panniculectomy," says Newland. The data indicates that even when standard prophylactic measures—such as the administration of anticoagulants—are employed, patients with a prior COVID-19 diagnosis exhibit a significantly higher incidence of clot-related complications compared to those who have never contracted the virus.
A Chronological Look at the Data
To reach these conclusions, researchers conducted a retrospective analysis of 7,114 patients who underwent functional panniculectomy between 2017 and 2023. This timeframe was strategically chosen to compare patient outcomes before and after the onset of the global COVID-19 pandemic.
The Pre-Pandemic Baseline (2017–March 2020)
In the years leading up to the pandemic, 3,015 patients underwent the procedure. During this period, the medical community relied on established clinical scoring systems, such as the Caprini Risk Assessment Model, to determine the appropriate dose and duration of blood-thinning medications for each patient. The baseline rate of VTE among this cohort was measured at 3.2%.
The Pandemic Era (March 2020–2023)
The study then transitioned to a cohort of 4,099 patients who underwent surgery after the start of the pandemic. Surprisingly, the initial aggregate analysis showed an overall VTE rate of 3.0%, which appeared to be statistically similar to the pre-pandemic figures. However, the research team recognized that this aggregate data might mask critical differences between subsets of the population.
The COVID-History Divergence
The most significant insights emerged when the researchers subdivided the post-pandemic cohort into two distinct groups: those with a documented history of COVID-19 (790 patients) and those without (3,309 patients). The findings revealed a stark contrast:
- Patients with a history of COVID-19: 4.9% developed VTE.
- Patients without a history of COVID-19: 2.5% developed VTE.
This disparity represents a nearly twofold increase in risk, suggesting that the "post-COVID" status is an independent variable that may necessitate a reassessment of how surgeons prepare these patients for the operating room.
Supporting Data: Why COVID-19 Matters in Surgery
The primary hypothesis driving this study is the concept of "hypercoagulability"—a condition where the blood has an increased tendency to clot. COVID-19 is known to cause significant inflammation of the vascular endothelium (the inner lining of blood vessels), which can persist for months after the acute infection has cleared.
The study authors noted that other traditional risk factors for VTE—such as pre-existing heart disease, lung conditions, and vascular health—were balanced across both the COVID and non-COVID groups. By controlling for these variables, the researchers were able to isolate the COVID-19 infection as the primary differentiator in the elevated clot rate.
While the study does not definitively claim that every post-COVID patient is at high risk, the statistical significance of the 4.9% rate is a "red flag" that warrants further investigation. The researchers emphasize that the inflammatory state induced by SARS-CoV-2 may fundamentally alter the coagulation cascade, making the surgical stress of a major body contouring procedure more likely to trigger a life-threatening clot.
Official Responses and Clinical Implications
The implications for the field of plastic and reconstructive surgery are profound. As surgeons continue to treat patients who have navigated the pandemic, the standard Caprini score—which has been the "gold standard" for VTE risk assessment for years—may need to be updated to explicitly include "History of COVID-19" as a high-risk indicator.
Adjusting Pre-Surgical Protocols
"This may have implications for assessment and prevention of surgical risks of body contouring surgery after major weight loss," Newland states. In practice, this could mean that surgeons may opt for:
- Extended Prophylaxis: Extending the duration of blood-thinner prescriptions post-surgery for patients with a history of COVID.
- Increased Screening: Implementing more rigorous pre-operative blood work to identify markers of residual hypercoagulability.
- Timing Adjustments: Waiting for a longer period between the patient’s COVID-19 infection and the scheduled elective surgery to allow the body’s inflammatory response to stabilize.
The medical community, including the American Society of Plastic Surgeons, is now tasked with evaluating whether these findings should be integrated into clinical guidelines. The study authors call for prospective, multicenter trials to confirm these results and to establish a standardized protocol for managing this new, emerging patient population.
Future Outlook: A New Paradigm in Surgical Care
As we move further into the post-pandemic era, the medical profession must adapt to the "long-tail" effects of the virus. The study published in Plastic and Reconstructive Surgery serves as a critical reminder that elective procedures, while functional and life-enhancing, are not immune to the systemic changes brought on by the global pandemic.
The conclusion of the report is clear: the patient population has changed. Surgeons must move beyond traditional risk assessment models and account for the invisible, long-term biological footprint of COVID-19. By acknowledging this new risk factor, practitioners can better protect their patients, reduce the incidence of preventable complications, and continue to provide safe, high-quality care in an increasingly complex medical landscape.
About the Research and Publication
The study, titled "Incidence of Postoperative Venous Thromboembolism following Panniculectomy in Patients with History of COVID-19," is available in the November 2025 issue of Plastic and Reconstructive Surgery. It represents a collaborative effort to bridge the gap between infectious disease history and surgical outcomes, providing a blueprint for future research into how viral infections impact surgical safety.
As plastic surgery continues to evolve, this data underscores the necessity of constant vigilance. Whether through updated risk calculators or revised recovery protocols, the goal remains the same: ensuring that patients seeking to improve their quality of life through surgery are not met with avoidable, life-threatening complications.
For further details on this study, readers are encouraged to consult the full text published by Wolters Kluwer in Plastic and Reconstructive Surgery (doi: 10.1097/PRS.0000000000012202).
About the Author
